Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial
Drug Design, Development and Therapy · 2024-07 · Volume 18 · 2729-2743
DOI: 10.2147/dddt.s461416 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2024-07. Verfasst von Yuncheng Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan, 410013, People's Republic o…. Hauptthemen laut MEDLINE: Chronic Pain, Dose-Response Relationship, Drug, Spiro Compounds, Thiophenes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain, The Third Xiangya Hospital and Institute of Pain Medicine, Central South University, Changsha, Hunan, 410013, People's Republic of China.
- Department of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China.
- Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, People's Republic of China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.
ORCID-Profile: Guoping Yang
Zitieren
APA
Ni, Y., Huang, R., Yang, S., Yang, X. Y., Zeng, S., Yao, A., Huang, J., & Yang, G. (2024). Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial. Drug Design, Development and Therapy, Volume 18, 2729-2743. https://doi.org/10.2147/dddt.s461416
Vancouver
Ni Y, Huang R, Yang S, Yang XY, Zeng S, Yao A, et al. Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial. Drug Design, Development and Therapy. 2024;Volume 18:2729-2743. doi:10.2147/dddt.s461416
BibTeX
@article{Ni2024,
author = {Ni, Yuncheng and Huang, Ranglang and Yang, Shuang and Yang, Xiao Yan and Zeng, Shan and Yao, An and Huang, Jie and Yang, Guoping},
title = {Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial},
journal = {Drug Design, Development and Therapy},
year = {2024},
volume = {Volume 18},
pages = {2729--2743},
doi = {10.2147/dddt.s461416}
}
EUVIMED